Search clinical trials for: Telapristone Acetate, Proellex 12 mg Formulation A

Total 87 results

Repros Therapeutics Inc.

Completed

Comparison of Two Formulations of Proellex for Oral Administration

Healthy

United States
Repros Therapeutics Inc.

Completed

Proellex® Pharmacokinetic Bridging Study II (PK)

Healthy

United States
Repros Therapeutics Inc.

Completed

Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200

Uterine Fibroids
Repros Therapeutics Inc.

Completed

Comparison of Two Formulations of Proellex for Vaginal Administration

Comparison of 2 Different Formulations of 12 mg Proellex Vaginal Capsules

United States
Repros Therapeutics Inc.

Completed

Extension of Study ZPV-200

Uterine Fibroids

United States
Repros Therapeutics Inc.

Terminated

Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Terminated

Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females

Renal Impairment

United States
Repros Therapeutics Inc.

Completed

Proellex Pharmacokinetics Bridging Study

Healthy

United States
Repros Therapeutics Inc.

Completed

Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults

Impaired Liver Function

United States
Repros Therapeutics Inc.

Completed

Crossover Study of the Safety and PK Properties of Proellex®

Pharmacokinetics

United States
Repros Therapeutics Inc.

Completed

Investigate Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose in Healthy Females

ABSORPTION | METABOLISM | EXCRETION

United States
Repros Therapeutics Inc.

Withdrawn

Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms

Uterine Fibroids

United States, Brazil
Repros Therapeutics Inc.

Completed

A Safety and Pharmacokinetic Study of Proellex® (PK)

Healthy

United States
Repros Therapeutics Inc.

Withdrawn

Open-Label Extension Study to ZPE-202

Endometriosis

United States
Repros Therapeutics Inc.

Terminated

Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Terminated

An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis

Endometriosis

United States
Repros Therapeutics Inc.

Completed

Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Terminated

Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids

Anemia | Uterine Fibroids

Mexico
Repros Therapeutics Inc.

Terminated

Study to Evaluate Menses Induction in Women Administered Proellex

Amenorrhea

United States
Repros Therapeutics Inc.

Terminated

Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

Determination of the Lowest, Safe and Effective Dose of Proellex

Amenorrhea

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy

Stage 0 Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Lobular Breast Carcinoma In Situ | Ductal Breast Carcinoma In Situ | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier

United States
Repros Therapeutics Inc.

Terminated

Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

Uterine Fibroids

United States, Mexico
Pfizer

Completed

A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese

Obesity | Overweight

United States
H. Lundbeck A/S

Completed

Bioequivalence Study of Idalopirdine Tablets 60 mg

Healthy

United Kingdom
Northwestern University
Breast Cancer Research Foundation; Repros Therapeutics Inc.

Unknown

Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer

Stage II Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer

United States
Novo Nordisk A/S

Completed

A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People

Diabetes Mellitus, Type 2

Germany
Lyndra Inc.

Terminated

Study Determining Gastric-Retentive and Modified Release Properties of Prototype Capsules in Healthy Subjects

Healthy | Gastric Retention

United Kingdom
Idorsia Pharmaceuticals Ltd.

Completed

Single-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-281959 / ACT-246475 in Healthy Male Subjects

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

France
H. Lundbeck A/S

Completed

A Study Investigating Tablet Formulations of Lu AF11167 in Healthy Subjects

Healthy

United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose

Relapse-Remitting Multiple Sclerosis

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).

Relapsing Remitting Multiple Sclerosis
Teva Neuroscience, Inc.

Completed

Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients (ENCORE)

Multiple Sclerosis
USDA, Western Human Nutrition Research Center
University of California, Davis

Completed

Vitamin A Bioavailability in Lactating Women With Marginal Vitamin A Status

Vitamin A Deficiency

Bangladesh
Repros Therapeutics Inc.

Completed

Comparison of Two Formulations of Androxal

Bioequivalence

United States
Clovis Oncology, Inc.

Completed

Safety and Pharmacokinetic Profiles of Two Formulations of CO-1.01 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

Netherlands
Robert S Berman MD

Recruiting

Effects of MRSA Bactericidal Gel To Promote Healing and Eliminate MRSA in cSSTI Vancogel(TM) (Vancogel(R))

Bacterial Infections | Wounds

United States
Teva Pharmaceutical Industries, Ltd.

Completed

Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Belgium, France, Germany, Israel, Italy, United Kingdom
Abbott

Completed

A Study of Leuprolide to Treat Prostate Cancer

Prostate Cancer

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.

Postmenopause | Postmenopausal Osteoporosis
University of Colorado, Denver
International Centre for Diarrhoeal Disease Research, Bangladesh

Completed

Effects of EED on Zn Absorption and Retention in Children From a Standard Dose (ZEED1)

Environmental Enteric Dysfunction | Vitamin A Deficiency | Zinc Deficiency

United States, Bangladesh
Fundación Pública Andaluza para la gestión de la...

Completed

Pharmacokinetic Food-effect Study of Abiraterone Acetate (AA) in Castration Resistant Prostate Cancer (ABIFOOD01)

Prostate Cancer

Spain
Repros Therapeutics Inc.

Completed

Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects

Drug Interactions

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety and Tolerability of Glatiramer Acetate (GLACIER)

Relapsing-Remitting Multiple Sclerosis

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.

Relapsing Remitting Multiple Sclerosis

3

Subscribe